These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36558901)

  • 1. Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion.
    Shea SM; Thomas KA; Rassam RMG; Mihalko EP; Daniel C; Sullenger BA; Spinella PC; Nimjee SM
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
    Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
    Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Thrombolytic Effect of
    Martinez de Lizarrondo S; Gakuba C; Herbig BA; Repessé Y; Ali C; Denis CV; Lenting PJ; Touzé E; Diamond SL; Vivien D; Gauberti M
    Circulation; 2017 Aug; 136(7):646-660. PubMed ID: 28487393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin.
    Patzke J; Budde U; Huber A; Méndez A; Muth H; Obser T; Peerschke E; Wilkens M; Schneppenheim R
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):860-70. PubMed ID: 25192242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
    Parker DN; Tasneem S; Farndale RW; Bihan D; Sadler JE; Sebastian S; de Groot PG; Hayward CP
    Thromb Haemost; 2016 Jul; 116(1):87-95. PubMed ID: 27052467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory Testing for von Willebrand Disease: The Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin.
    Just S
    Semin Thromb Hemost; 2017 Feb; 43(1):75-91. PubMed ID: 27978590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
    Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
    Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
    Hillarp A; Friedman KD; Adcock-Funk D; Tiefenbacher S; Nichols WL; Chen D; Stadler M; Schwartz BA
    Haemophilia; 2015 Nov; 21(6):837-45. PubMed ID: 26172561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
    Patzke J; Favaloro EJ
    Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
    Sagheer S; Rodgers S; Yacoub O; Dauer R; Mcrae S; Duncan E
    Haemophilia; 2016 May; 22(3):e200-7. PubMed ID: 27076201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T; Sadler JE
    J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays.
    Favaloro EJ; Mohammed S
    Thromb Res; 2014 Dec; 134(6):1292-300. PubMed ID: 25300811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
    Hayward CP; Moffat KA; Graf L
    Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
    Sobel M; McNeill PM; Carlson PL; Kermode JC; Adelman B; Conroy R; Marques D
    J Clin Invest; 1991 May; 87(5):1787-93. PubMed ID: 2022745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.
    de Maistre E; Volot F; Mourey G; Aho LS; Ternisien C; Briquel ME; Bertrand MA; Tardy B; Frotscher B; Nguyen P; Dumont L; Vandroux D; Hézard N; Trossaërt M
    Thromb Haemost; 2014 Oct; 112(4):825-30. PubMed ID: 25103956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.